Journal of Hematology, ISSN 1927-1212 print, 1927-1220 online, Open Access
Article copyright, the authors; Journal compilation copyright, J Hematol and Elmer Press Inc
Journal website https://jh.elmerpub.com

Original Article

Volume 14, Number 1, February 2025, pages 14-19

Low Rate of Central Nervous System Relapse of Diffuse Large B-Cell Lymphoma Despite Limited Use of Intrathecal Prophylaxis

Figure

Figure 1.
Figure 1. Diffuse large B-cell lymphoma (DLBCL) cases and the patient inclusions and exclusions. CNS: central nervous system.

Tables

Table 1. Patients’ Characteristics
 
CharacteristicPatients’ number%
CNS: central nervous system; IPI: international prognostic index; R-CHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Age (years), no (range)5616 - 87
Gender
  Male5857.50
  Female4342.50
Ann Arbor stage
  I98.90
  II2120.80
  III1716.80
  IV5049.50
CNS-IPI score
  High-risk2524.75
  Intermediate-risk4443.50
  Low-risk3231.70
Chemotherapy
  R-CHOP9493
  Other77.9
CNS relapse22.0

 

Table 2. Extranodal Sites Involved
 
Extranodal siteNumber%
GI: gastrointestinal.
Lung2726.00
Liver2019.80
Bone marrow2019.80
GI tract98.90
Kidneys54.95
Breast43.96
Testis22.00
Adrenal22.00

 

Table 3. Characteristics of 25 Patients With High-Risk CNS-IPI
 
ParameterPatients’ values, n (%)a
aNot otherwise specified. CNS: central nervous system; IPI: international prognostic index; IT: intrathecal.
Age (years), median (range)65 (14 - 87)
Gender
  Male16 (64)
  Female9 (36)
Ann Arbor stage
  III2 (8)
  IV23 (92)
CNS-IPI score, n (%)
  411 (44)
  513 (52)
  61 (4)
Follow-up (months), median (range)28 (4 - 114)
Patients alive at last follow-up14 (56)
CNS prophylaxis
  Received16 (64)
  Not received9 (36)
Number of IT chemotherapy injections, median (range)3 (1 - 6)